T. Rowe Price Associates
TDOC icon

T. Rowe Price Associates’s Teladoc Health TDOC Stock Holding History

T. Rowe Price Associates’s Portfolio TDOC Stock Details TDOC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.28M Buy
234,300
+29,395
+14% +$165K ﹤0.01% 2028
2025
Q4 		$1.44M Buy
204,905
+26,019
+15% +$204K ﹤0.01% 1914
2025
Q3 		$1.38M Buy
178,886
+19,074
+12% +$149K ﹤0.01% 1908
2025
Q2 		$1.39M Buy
159,812
+20,462
+15% +$148K ﹤0.01% 1821
2025
Q1 		$1.11M Buy
139,350
+663
+0.5% +$6.71K ﹤0.01% 1904
2024
Q4 		$1.26M Buy
138,687
+15,953
+13% +$154K ﹤0.01% 1874
2024
Q3 		$1.13M Buy
122,734
+22,605
+23% +$187K ﹤0.01% 1929
2024
Q2 		$980K Buy
100,129
+13,752
+16% +$168K ﹤0.01% 1906
2024
Q1 		$1.3M Buy
86,377
+5,188
+6% +$94.1K ﹤0.01% 1778
2023
Q4 		$1.75M Buy
81,189
+9,039
+13% +$167K ﹤0.01% 1601
2023
Q3 		$1.34M Buy
72,150
+4,501
+7% +$105K ﹤0.01% 1654
2023
Q2 		$1.71M Sell
67,649
-152,967
-69% -$3.85M ﹤0.01% 1545
2023
Q1 		$5.71M Sell
220,616
-107,312
-33% -$2.87M ﹤0.01% 1155
2022
Q4 		$7.75M Sell
327,928
-25,254
-7% -$681K ﹤0.01% 1097
2022
Q3 		$8.95M Buy
353,182
+36,051
+11% +$1.26M ﹤0.01% 1080
2022
Q2 		$10.5M Sell
317,131
-62,950
-17% -$2.67M ﹤0.01% 1313
2022
Q1 		$27.4M Buy
380,081
+18,182
+5% +$1.31M ﹤0.01% 1146
2021
Q4 		$33.2M Buy
361,899
+25,578
+8% +$3.06M ﹤0.01% 1143
2021
Q3 		$42.6M Sell
336,321
-161,042
-32% -$23.4M ﹤0.01% 1077
2021
Q2 		$82.7M Sell
497,363
-78,828
-14% -$12.8M 0.01% 858
2021
Q1 		$105M Sell
576,191
-249,279
-30% -$57.8M 0.01% 764
2020
Q4 		$165M Buy
825,470
+302,672
+58% +$61.5M 0.02% 572
2020
Q3 		$115M Sell
522,798
-561,860
-52% -$119M 0.01% 611
2020
Q2 		$207M Sell
1,084,658
-28,737
-3% -$5.04M 0.03% 464
2020
Q1 		$173M Buy
1,113,395
+535,358
+93% +$62.3M 0.03% 444
2019
Q4 		$48.4M Sell
578,037
-392,443
-40% -$29.9M 0.01% 921
2019
Q3 		$65.7M Sell
970,480
-117,620
-11% -$7.74M 0.01% 765
2019
Q2 		$72.3M Sell
1,088,100
-504,767
-32% -$29.4M 0.01% 754
2019
Q1 		$88.6M Sell
1,592,867
-117,093
-7% -$7.15M 0.01% 675
2018
Q4 		$84.8M Sell
1,709,960
-331,299
-16% -$20.3M 0.01% 646
2018
Q3 		$176M Buy
2,041,259
+190,911
+10% +$13.6M 0.03% 517
2018
Q2 		$107M Buy
1,850,348
+653,132
+55% +$31.9M 0.02% 636
2018
Q1 		$48.2M Sell
1,197,216
-789,446
-40% -$29.8M 0.01% 892
2017
Q4 		$69.2M Buy
1,986,662
+135,695
+7% +$4.51M 0.01% 754
2017
Q3 		$61.4M Buy
1,850,967
+1,528,166
+473% +$50.1M 0.01% 775
2017
Q2 		$11.2M Buy
322,801
+114,684
+55% +$3.34M ﹤0.01% 1300
2017
Q1 		$5.2M Sell
208,117
-107,091
-34% -$2.23M ﹤0.01% 1427
2016
Q4 		$5.2M Sell
315,208
-54,858
-15% -$932K ﹤0.01% 1415
2016
Q3 		$6.78M Buy
370,066
+161,316
+77% +$2.83M ﹤0.01% 1381
2016
Q2 		$3.34M Sell
208,750
-310,245
-60% -$3.62M ﹤0.01% 1446
2016
Q1 		$4.98M Buy
518,995
+302,245
+139% +$4.29M ﹤0.01% 1401
2015
Q4 		$3.89M Sell
216,750
-13,800
-6% -$255K ﹤0.01% 1454
2015
Q3 		$5.14M Buy
+230,550
New +$6.23M ﹤0.01% 1432

Other funds holding TDOC

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VC
Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates's TDOC Position: Q1 2026 in Review

T. Rowe Price Associates increased its Teladoc Health (TDOC) stake by 14% in Q1 2026, buying an estimated $165K and bringing the position to 234,300 shares worth $1.28M. The position accounts for ﹤0.01% of the portfolio, ranked #2028.

T. Rowe Price Associates first reported a position in TDOC in Q3 2015 and has held it in 43 quarters since. The position peaked at $207M in Q2 2020. 322 funds tracked by Wall St. Rank hold TDOC as of Q1 2026.

  • T. Rowe Price Associates held 234,300 shares of Teladoc Health worth $1.28M as of Q1 2026.
  • T. Rowe Price Associates bought 29,395 Teladoc Health shares in Q1 2026, an estimated $165K.
  • Teladoc Health made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #2028 holding.
  • T. Rowe Price Associates first reported a position in Teladoc Health in Q3 2015 and has held it in 43 quarters since.
  • T. Rowe Price Associates's Teladoc Health position peaked at $207M in Q2 2020.
  • 322 funds tracked by Wall St. Rank held Teladoc Health as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.